Table 2. Outcomes by Randomization Group.

	Systolic blood pressure target, mm Hg			Absolute difference (95% CI), mm Hg		Regression coefficient (95% CI)	P value for futility
	<140	<160	≤180	<140 vs ≤180	<160 vs ≤180
Primary outcomes, mean (95% CI)
Follow-up infarct volume at 36 h, mL	32.4 (18.0 to 46.7) [n = 38]	50.7 (33.7 to 67.7) [n = 36]	46.4 (24.5 to 68.2) [n = 39]	−14.0 (−39.8 to 11.8)	4.3 (−22.9 to 31.6)	−0.29 (−0.81 to ∞)a	.99
Utility-weighted mRS score at 90 d	0.51 (0.38 to 0.63) [n = 37]	0.47 (0.35 to 0.60) [n = 39]	0.58 (0.46 to 0.71) [n = 37]	−0.08 (−0.25 to 0.10)	−0.11 (−0.29 to 0.07)	−0.0019 (−∞ to 0.0017)b	.93
Secondary outcomes, No./total (%) c
Any ICH ≤36 h	14/39 (36)	12/37 (32)	12/40 (30)	5.9 (−14.8 to 26.6)	2.4 (−18.3 to 23.1)
Symptomatic ICH ≤36 h	2/37 (5)	1/35 (3)	2/37 (5)	0 (−10.3 to 10.3)	−2.5 (−11.7 to 6.6)
Post hoc outcomes c
In-hospital mortality, No./total (%)	3/40 (7.5)	6/40 (15)	3/40 (7.5)	0 (−11.5 to 11.5)	7.5 (−6.3 to 21.3)
24-hour NIHSS score, mean (95% CI)	11 (8 to 14) [n = 38]	12 (9 to 15) [n = 37]	7 (5 to 10) [n = 37]	3.9 (−0.2 to 7.9)	4.6 (0.6 to 8.6)

Abbreviations: ICH, intracerebral hemorrhage; mRS, modified Rankin Scale score; NIHSS, National Institutes of Health Stroke Scale.

^a Testing across all 3 groups, the regression coefficient denotes a 0.29 mL reduction in follow-up infarct volume with each mm Hg reduction in systolic blood pressure target after endovascular therapy (with a possibility of as much benefit as a 0.81-mL reduction and includes the regions of harm).

^b Testing across all 3 groups, the regression coefficient denotes a 0.0019 reduction in utility-weighted mRS score with each mm Hg reduction in systolic blood pressure target after endovascular therapy (with a small possible benefit of 0.0017 gain in utility and includes the regions of harm).

^c Secondary outcomes and in-hospital mortality absolute differences are presented as percentages.